Impact Diagnostics

Impact Diagnostics was a medical technology company dedicated to advancing cervical cancer screening through innovative collection and molecular testing platforms. The company's flagship product, the Gyn-Pak, was a proprietary collection system designed for both physician use and self-sampling to improve the accuracy of Pap smears and HPV detection. Beyond collection devices, the company developed the Impact-HPV molecular diagnostic test, which aimed to provide high-sensitivity detection of high-risk HPV strains. Based in Salt Lake City, Utah, Impact Diagnostics sought to reduce global cervical cancer mortality by providing more accessible and reliable screening tools for underserved populations. Although the company is no longer active, its technologies represented a significant effort in the transition toward molecular-based cervical screening.